Adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma

American Journal of Surgery

Volumn 195, Issue 6, 2008, Pages 757-762

  Murakami, Yoshiaki ^a   Uemura, Kenichiro ^a   Sudo, Takeshi ^a   Hayashidani, Yasuo ^a   Hashimoto, Yasushi ^a   Nakagawa, Naoya ^a   Ohge, Hiroki ^a   Sueda, Taijiro ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Gemcitabine; Pancreatic carcinoma; Postsurgical adjuvant chemotherapy; S 1; Two year survival rate

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; GEMCITABINE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; VOMITING;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OXONIC ACID; PANCREATECTOMY; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; SURVIVAL RATE; TEGAFUR;

EID: 44349154677     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2007.04.018     Document Type: Article

References (43)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
2. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
3. Murakami Y., Uemura K., Sasaki T., et al. Long-term survival of pancreatic cancer patient diagnosed by positive telomerase activity of pancreatic juice. Surgery 138 (2005) 962-963
4. Tan H.P., Smith J., and Garberoglio C.A. Pancreatic adenocarcinoma: an update. J Am Coll Surg 183 (1996) 164-184
5. Sener S.F., Fremgen A., Menck H.R., et al. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 189 (1999) 1-7
6. Winter J.M., Cameron J.L., Campbell K.A., et al. 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg 10 (2006) 1199-1211
7. Shimada K., Sakamoto Y., Sano T., et al. Prognostic factors after distal pancreatectomy with extended lymphadenectomy for invasive pancreatic adenocarcinoma of the body and tail. Surgery 139 (2006) 288-295
8. Moon H.J., An J.Y., Heo J.S., et al. Predicting survival after surgical resection for pancreatic ductal adenocarcinoma. Pancreas 32 (2006) 37-43
9. Tani M., Kawai M., Terasawa H., et al. Does postoperative chemotherapy have a survival benefit for patients with pancreatic cancer?. J Surg Oncol 93 (2006) 485-490
10. Brown K.M., Domin C., Aranha G.V., et al. Increased preoperative platelet count is associated with decreased survival after resection for adenocarcinoma of the pancreas. Am J Surg 189 (2005) 278-282
11. Wagner M., Redaelli C., Lietz M., et al. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 91 (2004) 586-594
12. Kuhlmann K.F., de Castro S.M., Wesseling J.G., et al. Surgical treatment of pancreatic adenocarcinoma: actual survival and prognostic factors in 343 patients. Eur J Cancer 40 (2004) 549-558
13. Richter A., Niedergethmann M., Sturm J.W., et al. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg 27 (2003) 324-329
14. Gebhardt C., Meyer W., Reichel M., et al. Prognostic factors in the operative treatment of ductal pancreatic carcinoma. Langenbecks Arch Surg 385 (2000) 14-20
15. Wenger F.A., Peter F., Zieren J., et al. Prognosis factors in carcinoma of the head of the pancreas. Dig Surg 17 (2000) 29-35
16. Sohn T.A., Yeo C.J., Cameron J.L., et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 4 (2000) 567-579
17. Farnell M.B., Pearson R.K., Sarr M.G., et al., Pancreas Cancer Working Group. A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 138 (2005) 618-630
18. Yeo C.J., Cameron J.L., Sohn T.A., et al. Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma: comparison of morbidity and mortality and short-term outcome. Ann Surg 229 (1999) 613-624
19. Pedrazzoli S., DiCarlo V., Dionigi R., et al., Lymphadenectomy Study Group. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Ann Surg 228 (1998) 508-517
20. Traverso L.W. Pancreatic cancer: surgery alone is not sufficient. Surg Endosc 2 Suppl (2006) S446-S449
21. Kalser M.H., and Ellenberg S.S. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120 (1985) 899-903
22. Bakkevold K.E., Arnesjo B., Dahl O., et al. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater-results of a controlled, prospective, randomised multicentre study. Eur J Cancer 29A (1993) 698-703
23. Klinkenbijl J.H., Jeekel J., Sahmoud T., et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230 (1999) 776-784
24. Takada T., Amano H., Yasuda H., et al. Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract. is postoperative adjuvant chemotherapy useful for gallbladder carcinoma?. A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 95 (2002) 1685-1695
25. Kosuge T., Kiuchi T., Mukai K., et al., Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer (JSAP). A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. Jpn J Clin Oncol 36 (2006) 159-165
26. Neoptolemos J.P., Stocken D.D., Friess H., et al., European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350 (2004) 1200-1210
27. Oettle H., Post S., Neuhaus P., et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297 (2007) 267-277
28. Stocken D.D., Buchler M.W., Dervenis C., et al., Pancreatic Cancer Meta-Analysis Group. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer 92 (2005) 1372-1381
29. Shirasaka T., Shimamato Y., Ohshimo H., et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7 (1996) 548-557
30. Tsujie M., Nakamori S., Nakahira S., et al. Schedule-dependent therapeutic effects of gemcitabine combined with Uracil-Tegafur in a human pancreatic cancer xenograft model. Pancreas 33 (2006) 142-147
31. Nakamura K., Yamaguchi T., Ishihara T., et al. Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer 94 (2006) 1575-1579
32. International Union Against Cancer. TNM Classification of Malignant Tumors. 6th ed. (2002), Wiley-Liss, New York, NY
33. Burris III H.A., Moore M.J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15 (1997) 2403-2413
34. Sakata Y., Ohtsu A., Horikoshi N., et al. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34 (1998) 1715-1720
35. Van den Brande J., Schoffski P., Schellens J.H., et al. EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. Br J Cancer 88 (2003) 648-653
36. Ueno H., Okusaka T., Ikeda M., et al. Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer 91 (2004) 1769-1774
37. Ueno H., Okusaka T., Ikeda M., et al. An early phase II study of S-1 in patients with metastatic pancreatic cancer. Oncology 68 (2005) 171-178
38. Picozzi V.J., Kozarek R.A., and Traverso L.W. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 185 (2003) 476-480
39. Yeo C.J., Abrams R.A., Grochow L.B., et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 225 (1997) 621-636
40. Spitz F.R., Abbruzzese J.L., Lee J.E., et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 15 (1997) 928-937
41. Foo M.L., Gunderson L.L., Nagorney D.M., et al. Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation +/- 5 fluorouracil. Int J Radiat Oncol Biol Phys 26 (1993) 483-489
42. Whittington R., Bryer M.P., Haller D.G., et al. Adjuvant therapy of resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 21 (1991) 1137-1143
43. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 59 (1987) 2006-2010